The U.S. Food and Drug Administration (FDA) recently issued “Diversity Action Plans to Improved Enrollment of Participants from Underrepresented Populations in Clinical Studies.”  This draft guidance “describes the form, content, and manner of diversity action plans, the applicable medical products, …

FDA Draft Guidance on Improving Underrepresented Population Enrollment in Clinical Studies Read more »

The U.S. Department of Justice (DOJ) Drug Enforcement Administration (DEA) recently announced it is proposing a rule to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).  [See 21 U.S.C. § 812 Schedules of controlled …

DEA Proposes Transferring Marijuana to Schedule III Read more »